S&P 500   4,580.40 (+0.63%)
DOW   35,670.42 (+0.51%)
QQQ   381.78 (+0.47%)
AAPL   149.82 (+0.65%)
MSFT   324.25 (+0.33%)
FB   312.53 (+0.10%)
GOOGL   2,941.97 (+0.60%)
TSLA   1,068.59 (+2.96%)
AMZN   3,402.22 (+0.29%)
NVDA   249.06 (+1.86%)
BABA   169.09 (-0.08%)
NIO   39.67 (+0.92%)
CGC   12.87 (+0.70%)
AMD   123.06 (+0.64%)
MU   69.52 (+1.88%)
T   25.12 (+0.24%)
F   16.90 (+8.96%)
DIS   170.05 (+0.29%)
PFE   42.98 (+0.02%)
BA   206.74 (+0.06%)
AMC   35.23 (+1.35%)
S&P 500   4,580.40 (+0.63%)
DOW   35,670.42 (+0.51%)
QQQ   381.78 (+0.47%)
AAPL   149.82 (+0.65%)
MSFT   324.25 (+0.33%)
FB   312.53 (+0.10%)
GOOGL   2,941.97 (+0.60%)
TSLA   1,068.59 (+2.96%)
AMZN   3,402.22 (+0.29%)
NVDA   249.06 (+1.86%)
BABA   169.09 (-0.08%)
NIO   39.67 (+0.92%)
CGC   12.87 (+0.70%)
AMD   123.06 (+0.64%)
MU   69.52 (+1.88%)
T   25.12 (+0.24%)
F   16.90 (+8.96%)
DIS   170.05 (+0.29%)
PFE   42.98 (+0.02%)
BA   206.74 (+0.06%)
AMC   35.23 (+1.35%)
S&P 500   4,580.40 (+0.63%)
DOW   35,670.42 (+0.51%)
QQQ   381.78 (+0.47%)
AAPL   149.82 (+0.65%)
MSFT   324.25 (+0.33%)
FB   312.53 (+0.10%)
GOOGL   2,941.97 (+0.60%)
TSLA   1,068.59 (+2.96%)
AMZN   3,402.22 (+0.29%)
NVDA   249.06 (+1.86%)
BABA   169.09 (-0.08%)
NIO   39.67 (+0.92%)
CGC   12.87 (+0.70%)
AMD   123.06 (+0.64%)
MU   69.52 (+1.88%)
T   25.12 (+0.24%)
F   16.90 (+8.96%)
DIS   170.05 (+0.29%)
PFE   42.98 (+0.02%)
BA   206.74 (+0.06%)
AMC   35.23 (+1.35%)
S&P 500   4,580.40 (+0.63%)
DOW   35,670.42 (+0.51%)
QQQ   381.78 (+0.47%)
AAPL   149.82 (+0.65%)
MSFT   324.25 (+0.33%)
FB   312.53 (+0.10%)
GOOGL   2,941.97 (+0.60%)
TSLA   1,068.59 (+2.96%)
AMZN   3,402.22 (+0.29%)
NVDA   249.06 (+1.86%)
BABA   169.09 (-0.08%)
NIO   39.67 (+0.92%)
CGC   12.87 (+0.70%)
AMD   123.06 (+0.64%)
MU   69.52 (+1.88%)
T   25.12 (+0.24%)
F   16.90 (+8.96%)
DIS   170.05 (+0.29%)
PFE   42.98 (+0.02%)
BA   206.74 (+0.06%)
AMC   35.23 (+1.35%)
NASDAQ:IMPL

Impel NeuroPharma Stock Forecast, Price & News

$10.07
-0.08 (-0.79 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.65
$10.39
50-Day Range
$9.42
$23.12
52-Week Range
$6.90
$34.75
Volume
278,033 shs
Average Volume
398,828 shs
Market Capitalization
$196.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMPL News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel NeuroPharma and its competitors with MarketBeat's FREE daily newsletter.


About Impel NeuroPharma

Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMPL
Employees
59
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$196.47 million
Next Earnings Date
11/15/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

2.33 out of 5 stars

Medical Sector

247th out of 1,372 stocks

Pharmaceutical Preparations Industry

112th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Impel NeuroPharma (NASDAQ:IMPL) Frequently Asked Questions

Is Impel NeuroPharma a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Impel NeuroPharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Impel NeuroPharma stock.
View analyst ratings for Impel NeuroPharma
or view top-rated stocks.

What stocks does MarketBeat like better than Impel NeuroPharma?

Wall Street analysts have given Impel NeuroPharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Impel NeuroPharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Impel NeuroPharma?

Impel NeuroPharma saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 784,800 shares, a decline of 16.5% from the September 30th total of 940,100 shares. Based on an average daily volume of 704,700 shares, the days-to-cover ratio is presently 1.1 days. Approximately 12.0% of the company's stock are sold short.
View Impel NeuroPharma's Short Interest
.

When is Impel NeuroPharma's next earnings date?

Impel NeuroPharma is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for Impel NeuroPharma
.

How were Impel NeuroPharma's earnings last quarter?

Impel NeuroPharma, Inc. (NASDAQ:IMPL) announced its quarterly earnings results on Monday, August, 16th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.19.
View Impel NeuroPharma's earnings history
.

What price target have analysts set for IMPL?

3 Wall Street analysts have issued twelve-month price objectives for Impel NeuroPharma's shares. Their forecasts range from $21.00 to $55.00. On average, they anticipate Impel NeuroPharma's share price to reach $36.00 in the next twelve months. This suggests a possible upside of 257.5% from the stock's current price.
View analysts' price targets for Impel NeuroPharma
or view top-rated stocks among Wall Street analysts.

Who are Impel NeuroPharma's key executives?

Impel NeuroPharma's management team includes the following people:
  • Mr. Adrian Adams, Chairman, CEO & Pres (Age 70) (LinkedIn Profile)
  • Dr. John D. Hoekman Ph.D., Co-Founder, Chief Technology & Devel. Officer and Director (Age 40)
  • Dr. John H. Leaman, Chief Financial Officer (Age 48)
  • Ms. Jennifer L. Berman, VP of Marketing
  • Ms. Patty Billingsley, VP of Sales
  • Mr. Leonard S. Paolillo, Chief Commercial Officer (Age 42)
  • Dr. Stephen Bevan Shrewsbury, Chief Medical Officer (Age 64)
  • Dr. Lynn C. Gold, Sr. VP of Regulatory Affairs (Age 64)
  • Mr. Scott Youmans, Sr. VP of Technical Operations (Age 54)

When did Impel NeuroPharma IPO?

(IMPL) raised $80 million in an initial public offering on Friday, April 23rd 2021. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO.

What is Impel NeuroPharma's stock symbol?

Impel NeuroPharma trades on the NASDAQ under the ticker symbol "IMPL."

When did Impel NeuroPharma's lock-up period expire?

Impel NeuroPharma's lock-up period expired on Wednesday, October 20th. Impel NeuroPharma had issued 5,333,334 shares in its IPO on April 23rd. The total size of the offering was $80,000,010 based on an initial share price of $15.00. Since the expiration of Impel NeuroPharma's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Impel NeuroPharma's major shareholders?

Impel NeuroPharma's stock is owned by a number of retail and institutional investors. Top institutional investors include FNY Investment Advisers LLC (0.03%). Company insiders that own Impel NeuroPharma stock include Adrian Adams, Global Strategic Fund I Venbio and Vivo Capital Viii, Llc.
View institutional ownership trends for Impel NeuroPharma
.

Which major investors are buying Impel NeuroPharma stock?

IMPL stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Impel NeuroPharma stock in the last two years include Adrian Adams, and Vivo Capital Viii, Llc.
View insider buying and selling activity for Impel NeuroPharma
or or view top insider-buying stocks.

How do I buy shares of Impel NeuroPharma?

Shares of IMPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Impel NeuroPharma's stock price today?

One share of IMPL stock can currently be purchased for approximately $10.07.

How much money does Impel NeuroPharma make?

Impel NeuroPharma has a market capitalization of $196.47 million.

How many employees does Impel NeuroPharma have?

Impel NeuroPharma employs 59 workers across the globe.

What is Impel NeuroPharma's official website?

The official website for Impel NeuroPharma is www.Impelnp.com.

How can I contact Impel NeuroPharma?

The company can be reached via phone at 206-568-1466.


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.